Sunday, 11 August 2024

Week 470 Review - Not a great week but Optibiotix helps it end in the black.

Not a great week, with more shares dropping than rising, but given the dreadful plummet on Monday, it could have been a lot worse. The deficit between cost and value actually improved by £2,779 thanks to a 1.5p rise in OPTI:Optibiotix. It now stands at £96,302, with deficit between injection amount and value at £28,948. Total portfolio value went up to £126,229.

Worst performer was CWR:Ceres Power, which dropped 8% to go 14% down. This one is really volatile, so I need to be able to sell something n my trading account, as trading these could be rewarding.

IPX:Impax Asset Management is at the very top of my magic formula ranking, but has been a disaster.They fell 8% this week and are already 23% down, and I've hardly had them any time at all. Given their place at the top of my ranking, I should really be buying more at this price.

EDV:Endeavour Mining made me glad I sold a load last week, as they dropped 7% and are now 23% down. So much for them going up when they got back into the FTSE 100 - quite the opposite!

APAX:Apax Global Alpha have slid down my magic formula ranking into the sell zone, but they fell 6% this week and are now 25% down, so it won't be happening any time soon.

AFC:AFC Energy were in profit not long ago, but they have plummeted recently, and dropped another 5% this week to go 23% down.

CORE:Solidcore Resources (formerly POLY:Polymetal) don't get a mention very often, as they are on the Astana index and I can't trade them. They are however making some progress, and went up 11% this week. That makes them still 85% down, so almost in junk territory, but I'm still hopeful they will re-list and make some sort of recovery.

OPTI:Optibiotix saw that I sold some last week so decided to go back up this week. It was only 1.5p, so not enough to reverse all last week's losses, but it's 8% and responsible for most of this week's gains.

Share of the Week is one I've been watching for years and is a rare example of good timing. ALU:Alumasc Group went up 8% and my holding is now up by 20% in just a few weeks. They are 39th in my magic formula rankings, so I wouldn't buy them now, but that's very high for an AIM company, so these deserve an accolade this week despite having the same increase as OPTI.

Here's the ISA and shares portfolio after week 2 of year 10.

Weekly Change
Cash £86.10 -£3.85
Portfolio cost £106,138.27 +£0
Portfolio sell value
(bid price-commission)
£56,137.80 (-47.1%) +£1,576.07
Potential profits £2,336.13 +£473.08
Yr 10 Dividends £0 +£0
Yr 10 Interest £0.06 +£0
Yr 10 Profit from sales £149.75 +£0
Yr 10 proj avg monthly profit £316.45 (4.9%) -£377.71
Total Dividends £12,222.49 +£0
Total Interest £6.86 +£0
Total Profit from sales £18,027.59 +£0
Average monthly cash profit £274.62 (4.3%) +£0.62
(Sold stocks profit + Dividends
- Fees / Months)
Compound performance 39% +0%

Cash went down due to monthly fees, and OPTI:Optibiotix went up so potential profits up £473 and decent rise in portfolio value. Year 10 performance will dive pretty quickly as I fail to make the same profit I did in week 1 in all the other weeks.


I guess it's the right direction


Still above the trend line which is nice.

The SIPP looks like this after week 454 overall and week 38 of year 9.




Weekly Change
Cash£544.15
-£16.66
Portfolio cost£113,625.55
+£0
Portfolio sell value
(bid price - commission)
£68,050.04(-40.1%)+£1,203.16
Potential profits£3,508.80
-£75.63
Yr 9 Dividends£924.61
+£0
Yr 9 Interest£4.36
+£0
Yr 9 Profit from sales£4,897.75
+£0
Yr 9 proj avg monthly profit£645.54(10.2%)-£19.39
Total Dividends£15,559.49
+£0
Total Interest£10.29
+£0
Total Profit from sales£15,733.65
+£0
Average monthly cash profit£286.45(4.5%)-£0.80
(Sold stocks profit + Dividends
- Fees / Months)
Compound performance40%+0%

A very quiet week, with monthly fees dropping cash, potential profits just dropping a little, and OPTI:Optibiotix sending value up.


I want to get back near that injection line!


Tiny up-tick isn't doing much to pull back that massive deficit.

The trading account looks like this after week 420 overall and week 4 of year 9.




Weekly Change
Cash£63.39
+£0
Portfolio cost£2,073.87
+£0
Portfolio sell value
(bid price - commission)
£1,347.81(-35.0%)+£0
Potential profits£0    
+£0
Year 9 Dividends£0
+£0
Year 9 Interest£0
+£0
Year 9 Profit£0
+£0
Yr 8 proj avg monthly profit£0(+0%)+£0
Dividends£85.46
+£0
Interest£0.03
+£0
Profit from sales-£602.54
+£0
Average monthly cash profit-£5.33(-3.1%)+£0.02
(Sold stocks profit + Dividends
- Fees / Months)

All share prices stayed the same in this one, so nothing changed apart from long term performance improving by 2p as the loss is spread over another week.


Flattest week ever


Below the trend line is bad.

No prospect of much happening next week. My SIPP shares that are outside the top 50 in my magic formula ranking are APAX:Apax Global Alpha (-25%), ARBB:Arbuthnot Banking (-13%), CAPD:Capital (-14%), GSK:GSK (-5%), WHR:Warehouse REIT (-23%), NG.:National Grid (+2%), EDV:Endeavour Mining (-23%), ATYM:Atalya Mining  (-22%), FXPO:Ferrexpo (-90%), AAL:Anglo American Mining (-11%) and UKW:Greencoat UK Wind (-6%).

I didn't really buy NG.:National Grid because of the magic formula rankings, so I'll probably hold onto those, as their metrics don't work to well for a ranking system due to massive debt. I'd like to have one utility and that's the one I'll keep.

It's a similar situation with GSK:GSK, which I didn't buy because of the magic formula, but I'm in two minds as to whether buying them was a mistake, so I may get rid.

Out of the others, the one with the least losses is UKW:Greencoat UK Wind. That's actually plummeted to 287th in the ranking, so I can't keep them despite the nice dividend. I've had £79 dividend from these, so whatever I sell them for will have an additional 5% return for that. I'll liberate £1,500 if I sell them, so will maybe get KNOS:Kainos Group with the proceeds, as they are 14th in my ranking, and some more CAML:Central Asia Metals with the other £500.

No comments:

Post a Comment